Form 4: Elanco CFO Buys 6,950 Shares Under 10b5-1 Plan
Insider Transaction Report
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, purchased 6,950 shares of common stock for approximately $150,596 under a Rule 10b5-1 plan.
Summary
- Robert M. VanHimbergen, Elanco Animal Health Inc.'s Executive Vice President and Chief Financial Officer, acquired 6,950 shares of the company's common stock.
- The transaction occurred on December 11, 2025, at a weighted average price of $21.6441 per share.
- The total value of the shares purchased amounts to approximately $150,596.
- The purchase was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.
- Following this transaction, VanHimbergen beneficially owns 124,233 shares of Elanco common stock.
- The reported balance includes 7,426 shares that were previously omitted from the reporting person's last Form 4 filing.
Sentiment
Score: 8
Explanation: The purchase of a significant number of shares by a key executive, especially the CFO, indicates strong insider confidence in the company's valuation and future performance, which is generally a bullish signal for investors.
Positives
- The EVP and CFO's purchase of 6,950 shares signals strong insider confidence in Elanco Animal Health's future prospects and current valuation.
- The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned investment decision rather than a reactive one, which can be viewed positively by investors.
Future Outlook
The filing does not contain specific forward-looking statements or guidance regarding the company's future performance.
Industry Context
Insider buying, particularly by a CFO, is often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or expects positive developments. This action aligns with a broader trend where executives invest in their own companies, signaling confidence to the investment community.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was made pursuant to a contract, instruction, or written plan for the purchase of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 12/11/2025 | This indicates a pre-planned, non-discretionary trade, which can mitigate concerns about executives trading on material non-public information. |
Stakeholder Impact
- Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value and future growth, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| 12/11/2025 | Date of common stock acquisition by Robert M. VanHimbergen. |
| 12/15/2025 | Date the Form 4 was filed with the SEC. |
Recommendation
buyThe EVP and CFO's purchase of company stock, particularly under a Rule 10b5-1 plan, suggests a belief in the company's undervaluation or strong future prospects. This action is often interpreted by seasoned investors as a bullish signal, indicating management's conviction in the company's trajectory and making the stock a potential 'buy' candidate.
Keywords
Elanco Animal Health, ELAN, Insider Buying, Form 4, Executive Stock Purchase, Robert M. VanHimbergen, CFO, 10b5-1 Plan, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.